Abstract
Psoriasis is one of the most prevalent chronic inflammatory diseases of the skin. The Wnt pathways have been documented to play
essential role in stem cell self-renewal and keratinocyte differentiation in the skin. Antagonizing the Wnt5a protein would emerge
as a novel therapeutics in psoriasis treatment. In this view, we have developed and characterized series of compounds by attaching
varied tertiary alkyloxy carbonyl groups at the N-terminal end of the hexapeptide (Met-Asp-Gly-Cys-Glu-Leu) bestowed to inhibit
Wnt/Ca2+ signaling in psoriasis. Hexapeptide compound with 1,1-diphenylethoxy carbonyl group attached to N-terminal end of
hexapeptide demonstrated highest binding affinity amongst all the evaluated compounds. The compound identified in the study
can be subjected further for
in vitro
and
in vivo
studies for ADMET properties.